The relation between coronary thrombolysis and coagulation variables 
Thrombolytic drugs reduced mortality in patients with acute myocardial infarction treated within 6, 12, or even 24 hours of the onset of symptoms.1 When treatment was started within the first 4-6 hours after the onset of chest pain, reperfusion was shown in most of the infarct related coronary arteries. However, in up to 30-40% of the patients no reperfusion could be achieved.4 Failure of thrombolytic treatment has been reported irrespective of the drug used.4 The configuration of coronary obstruction may be an important determinant of the success of treatment,5 but inhibition of drug activity has never been ruled out.
In general, streptokinase and anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) caused comparable changes in haematological variables such as fibrinogen, plasminogen, and a2 antiplasmin during the first 24 hours after they were given.' These changes were ascribed to systemic effects. Some patients, however, showed no substantial decrease in plasma fibrinogen after anistreplase or streptokinase administration.7 This suggests resistance to these drugs. It has been suggested that a systemic lytic state, defined as a low plasma concentration of fibrinogen after thrombolytic treatment, is a prerequisite for local thrombolytic efficacy.8
To investigate the possibility of drug resistance as an explanation for failure of thrombolytic treatment, we performed a retrospective study to assess the relation between the systemic fibrinolytic effects and the local efficacy of anistreplase in patients with acute myocardial infarction.
Patients and methods

PATIENTS
We studied 58 consecutive patients (47 men, 11 women), mean age 57 years (range 34-71), who presented within 4 hours of the onset of chest pain. Selection criteria for thrombolytic treatment included the presence of characteristic symptoms of myocardial infarction and ST segment elevation of at least 0 1 mV in one or more of the standard leads or at least 0-2 mV in two or more of the precordial leads in a 12 lead electrocardiogram and the presence of symptoms unresponsive to sublingual glyceryl trinitrate. We excluded patients with contraindications for thrombolytic treatment and those who had been treated with streptokinase or anistreplase within the previous 6 months. STUDY 
PROTOCOL
Patients were treated with 30 U of anistreplase (Eminase, SmithKline Beecham) administered intravenously in 4-5 minutes. Infusion with heparin (30 000 U in 24 hours) was started 4-6 hours after thrombolytic treatment and was continued until an adequate level of anticoagulation had been achieved with oral acenocoumarol, which was started after 48-72 hours. To assess patency of the infarct related artery, coronary angiography was performed 48 hours (range 36-60) after the administration of anistreplase in all patients. In the first 30 consecutive patients patency was also assessed after 90 minutes (range 1 to 3 hours). Patency was documented according to the score used in the thrombolysis in myocardial infarction (TIMI) trial. (table 1) . After 90 minutes, fibrinogen, plasminogen, and a2 antiplasmin concentrations were significantly reduced in both the lytic and nonlytic groups. Mean plasma concentrations of fibrinogen in the lytic and the non-lytic groups were 0-0 g/l and 2-3 g/l (normal range 1-7-3-5); of plasminogen 11% and 57% (normal range 70-130); and of a2 antiplasmin 4% and 35% (normal range 90-130) respectively. These differences were statistically significant. Individual values for fibrinogen in the six nonlytic patients before and 90 minutes after treatment with anistreplase were: 3-3 v 2-7; 2 7 v 23; 24v 1 1; 3v 22; 24 v 1-8, and 37v 3-6 g/l respectively. The reptilase time was considerably prolonged in the lytic group from 19 to 109 seconds but did not change in the non-lytic group (19 v 24 seconds). Euglobulin clot lysis time was shortened from > 120 before to < 10 minutes after the administration of anistreplase in both groups (normal value > 120 minutes). Serum concentrations of fibrinogen/fibrin degradation products remained within normal ranges (< 8 Mg/ml) in the non-lytic group, whereas they were considerably increased in the lytic group (median value >256 Mg/ml). Lew et al showed that high residual fibrinogen concentrations identified patients in whom thrombolytic treatment was relatively ineffective.'7 It is difficult to compare the results of these studies. In the first three studies intracoronary streptokinase or urokinase was given, whereas in Lew et al's study streptokinase was administered intravenously. The dosages of streptokinase varied widely as did the interval between onset of chest pain and thrombolytic treatment. Finally, a systemic lytic state was defined differently in these studies-as a reduction in fibrinogen of at least 50%,'5 of at least 10%8 or to below 0-5 g/l," and Burket et al did not define a cut off point.'6 Marder et al studied 106 patients treated with streptokinase or anistreplase.7 A systemic lytic state was defined as a fall of > 20% in plasma fibrinogen concentration. In 4 of the 58 patients treated with 30 U of anistreplase a systemic non-lytic state was found and none of these patients achieved reperfusion. None the less, no statistically significant relation between a systemic non-lytic state and failure of reperfusion was found. In the remaining 48 patients treated with a low dose of intracoronary streptokinase there was also no statistical correlation. Despite the presence of a systemic non-lytic state reperfusion occurred in 10 patients. This discrepancy was partly explained by local thrombolytic effects of intracoronary streptokinase.
In our patients we regarded a systemic lytic state as being likely if the concentration of plasma fibrinogen was <1 0 g/l 90 minutes after the administration of anistreplase. This value was chosen because it is commonly accepted as the haemostatic concentration of fibrinogen."8 In the lytic group there was an almost complete depletion of fibrinogen, plasminogen, and a2 antiplasmin, associated with a short euglobulin clot lysis time, considerably prolonged reptilase time, and a high concentration of fibrinogen/fibrin degradation products. In both the lytic and the non-lytic patients there was a comparable shortening of the euglobulin clot lysis time. Euglobulin clot lysis time reflects the fibrinolytic activity of plasma after inhibitors have been removed. Apparently, the fibrinolytic system was activated by anistreplase in all patients. The moderate decrease in plasminogen and a2 antiplasmin in the non-lytic group also accorded with activation of the fibrinolytic system. Because neither reptilase time nor the concentration of fibrinogen/fibrin products changed, whereas the fibrinogen concentration decreased but remained within normal ranges, it seems likely that inhibition was responsible for the limited expression of fibrinolytic activity.
None of the patients in the non-lytic group showed reperfusion of the infarct related vessel. Thus fibrinolytic inhibition seems to be restricted not only in terms of systemic effects but also for local thrombolytic failure. Initial plasma concentrations of a2 antiplasmin were similar in both groups. Therefore, it is unlikely that this potent inhibitor is responsible for the supposed fibrinolytic inhibition. Anti-streptokinase antibodies from earlier treatment with streptokinase or anistreplase can be excluded because none of the patients had previously received one of these drugs. There may have been naturally occurring anti-streptokinase antibodies,'9 but they were not sought in our patients.
A systemic non-lytic state 90 minutes after the administration of anistreplase in a proportion of patients with myocardial infarction predicted failure of thrombolysis. The absence of systemic and local fibrinolytic activity was probably due to fibrinolytic inhibitors. These compounds are currently under investigation. The reported findings are relevant not only to explain the mechanism of thrombolytic failure but may also have implications for clinical practice. A simple and rapid laboratory test to detect thrombolytic failure of anistreplase would lead to the option of additional treatment.
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